EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network

Marilena Di Napoli, Elisabetta Coppola, Carmine D'Aniello, Sarah Scagliarini iD, Carlo Buonerba, Andrea Muto, Luigi Formisano iD, Francesco Sabbatino, Davide Bosso, Sabrina Rossetti, Lorenzo Lobianco iD, Rosa Tambaro und 18 weitere

Current Oncology · 30.05.2026 · 33 (6) · 325

DOI: 10.3390/curroncol33060325 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, online erschienen am 30.05.2026. Verfasst von Marilena Di Napoli und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Gynecology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', 80131 Naples, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Antibodies, Monoclonal, Humanized, Axitinib, Kidney Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitor–tyrosine kinase inhibitor combinations represent a standard first-line option for metastatic renal cell carcinoma (mRCC). However, patients enrolled in pivotal trials often differ from those treated in routine practice. We report real-world outcomes of pembrolizumab plus axitinib within the Campania Oncology Network.

Methods

We conducted a multicenter retrospective study including consecutive treatment-naïve mRCC patients who received first-line pembrolizumab plus axitinib between January 2021 and November 2023 across eight regional centers. The primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints included objective response rate (ORR) and safety.

Results

A total of 117 patients were included. IMDC risk was favorable in 19.6%, intermediate/poor in 65%, and unknown in 15.4%. Median age was 59 years, and 53.8% had ECOG performance status ≥ 1. Clear-cell histology accounted for 87.2% of cases; brain metastases were present in 36%. After a median follow-up of 12.8 months, median PFS was 15.1 months (95% CI 9.6–NR), and median OS was not reached. ORR was 27.3%, with a disease control rate of 79.5%; patients with non-clear-cell histology showed an ORR of 41.7%. Disease progression was the main cause of treatment discontinuation (49%), while adverse events (AEs) led to discontinuation in 6% of cases. Grade ≥3 AEs occurred in 14% of patients. Most toxicities were grade 1–2, including diarrhea (23.9%), asthenia (18%), hypothyroidism (12.8%), and hypertension (9.4%). Grade 1–2 AEs were significantly more frequent in females compared with males (57.6% vs. 35.7%, p = 0.05).

Conclusions

In this consecutive regional cohort, pembrolizumab plus axitinib showed clinically relevant disease control, although ORR was lower than in pivotal trials. Performance status emerged as a key prognostic factor. Real-world data from oncology networks may support personalized first-line treatment decisions in mRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellAntibodies, Monoclonal, HumanizedAxitinibKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultNeoplasm Metastasis

Stichwörter der Autor:innen

TKIaxitinibimmunotherapymetastatic renal cell carcinomapembrolizumabreal-world datareal-world evidence

Substanzen

Antibodies, Monoclonal, HumanizedAxitinibpembrolizumab

Autor:innen und Institutionen

  • Department of Urology and Gynecology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', 80131 Naples, Italy.
  • Division of Medical Oncology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy.
  • Department of Medical Oncology, AORN "A. Cardarelli", 80131 Naples, Italy.
  • Oncology Unit, "Andrea Tortora" Hospital, 84016 Pagani, Italy.
  • Division of Medical Oncology, "San Giuseppe Moscati" Hospital, 83100 Avellino, Italy.
  • Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80138 Napoli, Italy.

ORCID-Profile: Sarah Scagliarini, Luigi Formisano, Lorenzo Lobianco, Maria Adelina Simeoni, Salvatore Stilo

Zitieren

APA

Di Napoli, M., Coppola, E., D'Aniello, C., Scagliarini, S., Buonerba, C., Muto, A., Formisano, L., Sabbatino, F., Bosso, D., Rossetti, S., Lobianco, L., Tambaro, R., Di Costanzo, F., Rescigno, P., Pisano, C., Cecere, S. C., Passarelli, A., Ventriglia, J., Calvanese, G., …, & Pignata, S. (2026). Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network. Current Oncology, 33(6), 325. https://doi.org/10.3390/curroncol33060325

Vancouver

Di Napoli M, Coppola E, D'Aniello C, Scagliarini S, Buonerba C, Muto A, et al. Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network. Current Oncology. 2026;33(6):325. doi:10.3390/curroncol33060325

BibTeX
@article{DiNapoli2026,
  author = {Di Napoli, Marilena and Coppola, Elisabetta and D'Aniello, Carmine and Scagliarini, Sarah and Buonerba, Carlo and Muto, Andrea and Formisano, Luigi and Sabbatino, Francesco and Bosso, Davide and Rossetti, Sabrina and Lobianco, Lorenzo and Tambaro, Rosa and Di Costanzo, Fabrizio and Rescigno, Pasquale and Pisano, Carmela and Cecere, Sabrina Chiara and Passarelli, Anna and Ventriglia, Jole and Calvanese, Gabriele and Lamia, Maria Rosaria and Perri, Erica and Contieri, Roberto and Franzese, Dario and Simeoni, Maria Adelina and Giorgio, Caterina Mariarosaria and Feroce, Florinda and Stilo, Salvatore and Pacifico, Giovanni and Canciello, Giuseppina and Pignata, Sandro},
  title = {Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {6},
  pages = {325},
  doi = {10.3390/curroncol33060325}
}
Kostenlos starten →